Severe anaphylaxis caused by intravenous anti-cancer drugs.
anaphylaxis
drug hypersensitivity
medical oncology
retrospective studies
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
14
08
2021
received:
26
04
2021
accepted:
20
08
2021
pubmed:
11
9
2021
medline:
11
3
2022
entrez:
10
9
2021
Statut:
ppublish
Résumé
The incidence and risk factors of severe anaphylaxis by intravenous anti-cancer drugs are unclear, whereas those of milder reactions have been reported. Electronic medical charts of cancer patients who have undergone intravenous chemotherapy between January 2013 and October 2020 in a university hospital were retrospectively reviewed. Non-epithelial malignancies were also included in the analysis. "Severe anaphylaxis" was judged using Brown's criteria: typical presentation of anaphylaxis and one or more of hypoxia, shock, and neurologic compromise. (UMIN000042887). Among 5584 patients (2964 males [53.1%], 2620 females [46.9%], median age 66 years), 88,200 person-day anti-cancer drug administrations were performed intravenously, and 27 severe anaphylaxes were observed. The causative drugs included carboplatin (14 cases), paclitaxel (9 cases), and cisplatin, docetaxel, trastuzumab, and cetuximab (1 case each). The person-based lifetime incidence of severe anaphylaxis for patients who received at least one intravenous chemotherapy was 0.48% (27/5584, 95% confidence interval (CI) 0.30%-0.67%) and the administration-based incidence was 0.031% (27/88,200, 95% CI 0.019%-0.043%). Among 124 patients who received at least 10 carboplatin administrations, 10 patients experienced carboplatin-induced severe anaphylaxis (10/124, 8.1%, 95% CI 3.0%-13.1%). Carboplatin caused severe anaphylaxis after at least 9-min interval since the drip started. Thirteen out of 14 patients experienced carboplatin-induced severe anaphylaxis within a 75-day interval from the previous treatment. Paclitaxel infusion caused severe anaphylaxis after a median of 5 min after the first drip of the day at a life-long incidence of 0.93% (9/968, 95% CI 0.27%-1.59%). We elucidated the high-risk settings of chemotherapy-induced severe anaphylaxis.
Sections du résumé
BACKGROUND
The incidence and risk factors of severe anaphylaxis by intravenous anti-cancer drugs are unclear, whereas those of milder reactions have been reported.
STUDY DESIGN
Electronic medical charts of cancer patients who have undergone intravenous chemotherapy between January 2013 and October 2020 in a university hospital were retrospectively reviewed. Non-epithelial malignancies were also included in the analysis. "Severe anaphylaxis" was judged using Brown's criteria: typical presentation of anaphylaxis and one or more of hypoxia, shock, and neurologic compromise. (UMIN000042887).
RESULTS
Among 5584 patients (2964 males [53.1%], 2620 females [46.9%], median age 66 years), 88,200 person-day anti-cancer drug administrations were performed intravenously, and 27 severe anaphylaxes were observed. The causative drugs included carboplatin (14 cases), paclitaxel (9 cases), and cisplatin, docetaxel, trastuzumab, and cetuximab (1 case each). The person-based lifetime incidence of severe anaphylaxis for patients who received at least one intravenous chemotherapy was 0.48% (27/5584, 95% confidence interval (CI) 0.30%-0.67%) and the administration-based incidence was 0.031% (27/88,200, 95% CI 0.019%-0.043%). Among 124 patients who received at least 10 carboplatin administrations, 10 patients experienced carboplatin-induced severe anaphylaxis (10/124, 8.1%, 95% CI 3.0%-13.1%). Carboplatin caused severe anaphylaxis after at least 9-min interval since the drip started. Thirteen out of 14 patients experienced carboplatin-induced severe anaphylaxis within a 75-day interval from the previous treatment. Paclitaxel infusion caused severe anaphylaxis after a median of 5 min after the first drip of the day at a life-long incidence of 0.93% (9/968, 95% CI 0.27%-1.59%).
CONCLUSION
We elucidated the high-risk settings of chemotherapy-induced severe anaphylaxis.
Identifiants
pubmed: 34505396
doi: 10.1002/cam4.4252
pmc: PMC8525120
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7174-7183Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Clin Rev Allergy Immunol. 2003 Jun;24(3):253-62
pubmed: 12721396
Gynecol Oncol. 2007 Apr;105(1):81-3
pubmed: 17157366
Nat Rev Drug Discov. 2010 Apr;9(4):325-38
pubmed: 20305665
N Engl J Med. 2008 Mar 13;358(11):1109-17
pubmed: 18337601
J Allergy Clin Immunol. 1994 Oct;94(4):666-8
pubmed: 7930298
J Allergy Clin Immunol. 2009 Jun;123(6):1262-7.e1
pubmed: 19501233
J Allergy Clin Immunol. 2004 Aug;114(2):371-6
pubmed: 15316518
Front Immunol. 2017 Nov 08;8:1472
pubmed: 29163536
J Allergy Clin Immunol. 1996 Oct;98(4):841-3
pubmed: 8876561
J Allergy Clin Immunol. 2001 Nov;108(5):861-6
pubmed: 11692116
J Clin Oncol. 1990 Jul;8(7):1263-8
pubmed: 1972736
Ann Allergy Asthma Immunol. 2009 Mar;102(3):179-87; quiz 187-9, 222
pubmed: 19354063
World Allergy Organ J. 2008 Jul;1(7 Suppl):S18-26
pubmed: 23282530
Cancer Med. 2021 Oct;10(20):7174-7183
pubmed: 34505396
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
J Clin Oncol. 1993 May;11(5):885-90
pubmed: 8098057
Oncology. 2001;61 Suppl 2:58-66
pubmed: 11694789
Gynecol Oncol Rep. 2017 Dec 14;23:7-9
pubmed: 29892682
Eur J Cancer. 2005 Oct;41(15):2262-7
pubmed: 16154353
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287
pubmed: 28404157
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):615-20
pubmed: 18754135
Ann Oncol. 2017 Jul 1;28(suppl_4):iv100-iv118
pubmed: 28881914
Int J Gynecol Cancer. 2005 Jan-Feb;15(1):13-8
pubmed: 15670291
Circulation. 2000 Aug 22;102(8 Suppl):I129-35
pubmed: 10966670
Oncologist. 2007 May;12(5):601-9
pubmed: 17522249
J Clin Oncol. 1999 Apr;17(4):1141
pubmed: 10561172
Gynecol Oncol. 2010 Mar;116(3):326-31
pubmed: 19944454
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):304-10
pubmed: 23642625